SeoulMarkets · tag
rights-issue
6 stories tagged “rights-issue”, each from official Korean data with its source and timestamp.
Cellid Raised 10 Billion Won by Diluting Shares 16 Percent
A single third-party placement filed today adds 4.8 million new Cellid shares to a base of 29.5 million — 16.26% dilution, with the company's own filing marking 9.999 billion of the roughly 10 billion won raised as general operating funds.
Four Korean Dilution Filings Landed in Three Weeks. One Tops 100 Percent.
Korea Advanced Materials issued two same-day, same-price convertible bonds worth a combined 20.62% dilution — the fourth of four unrelated dilution filings we checked from early September to today, ranging from 8% to 164%.
One Korean private placement diluted shares by 80 percent. Another, by 106 percent.
NC& and Satoshi Holdings each filed third-party share placements this month. NC&'s new shares equal 79.7% of its prior count; Satoshi's new shares exceed its prior count outright, at 105.9%.
EcoPro BM's ₩886bn raise: 100% for an unnamed acquisition
EcoPro BM's rights issue creates 9,900,990 new shares at ₩89,500 — a 16% discount to the ₩106,500 close — diluting existing holders 9.2%. All ₩886.1bn raised is filed as 'business acquisition'; no target has been separately disclosed.
From Celltrion to KG Mobility, one flaw repeats
This week we ranked 35 Korean capital-raising filings three ways — buybacks, rights issues, convertible bonds. In every single one, the size of the deal did not predict what it meant for existing shareholders.
Samsung Biologics raised 300x more, diluted 11x less
Samsung Biologics' ₩3.00tn rights issue diluted shareholders 4.7%. PhionX raised 300 times less — and diluted 53.8%, eleven times more. Twenty-one filings this week show size doesn't predict dilution.